Bristol Myers Squibb is purchasing an Nvidia DGX SuperPOD built on the chipmaker’s Vera Rubin architecture to support artificial intelligence use across its drug discovery and development operations. The pharmaceutical company said it will be the first life sciences group to acquire a DGX SuperPOD based on Vera Rubin. Nvidia introduced the architecture earlier this [...] The post Bristol Myers Squibb buys Nvidia AI system for drug discovery appeared first on AI News.